Island Pharmaceuticals Ltd (ILA) - Total Liabilities
Based on the latest financial reports, Island Pharmaceuticals Ltd (ILA) has total liabilities worth AU$336.43K AUD (≈ $238.04K USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Island Pharmaceuticals Ltd - Total Liabilities Trend (2019–2024)
This chart illustrates how Island Pharmaceuticals Ltd's total liabilities have evolved over time, based on quarterly financial data. See Island Pharmaceuticals Ltd (ILA) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Island Pharmaceuticals Ltd Competitors by Total Liabilities
The table below lists competitors of Island Pharmaceuticals Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
TagMaster AB Series B
ST:TAGM-B
|
Sweden | Skr209.37 Million |
|
EML Payments Ltd
F:A8Y1
|
Germany | €2.54 Billion |
|
Africa Energy Corp
V:AFE
|
Canada | CA$316.00K |
|
Sai Gon Ground Services JSC
VN:SGN
|
Vietnam | ₫360.00 Billion |
|
GAMING INNOVATION DL 1
F:GI11
|
Germany | €174.54 Million |
|
Handok
KO:002390
|
Korea | ₩512.43 Billion |
|
Invesco High Income Trust II
NYSE:VLT
|
USA | $33.17 Million |
|
d1000 Varejo Farma Participações S.A
SA:DMVF3
|
Brazil | R$1.03 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down Island Pharmaceuticals Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Island Pharmaceuticals Ltd stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 22.27 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.04 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Island Pharmaceuticals Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Island Pharmaceuticals Ltd (2019–2024)
The table below shows the annual total liabilities of Island Pharmaceuticals Ltd from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | AU$336.43K ≈ $238.04K |
-67.83% |
| 2023-12-31 | AU$1.05 Million ≈ $739.85K |
+296.30% |
| 2022-12-31 | AU$263.85K ≈ $186.69K |
-54.57% |
| 2021-12-31 | AU$580.73K ≈ $410.91K |
+145.21% |
| 2020-12-31 | AU$236.83K ≈ $167.57K |
+35037.98% |
| 2019-12-31 | AU$674.00 ≈ $476.90 |
-- |
About Island Pharmaceuticals Ltd
Island Pharmaceuticals Limited, a drug repurposing company, focuses on the development of antiviral therapeutics for antiviral therapeutics in Australia and the United States of America. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases. Island Pharmaceuticals Limited was founded in 2017 and is based in Hawthorn East,… Read more